Running Oak Capital LLC Sells 8,331 Shares of IQVIA Holdings Inc. $IQV

Running Oak Capital LLC trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 8.4% during the 3rd quarter, HoldingsChannel reports. The firm owned 90,746 shares of the medical research company’s stock after selling 8,331 shares during the quarter. IQVIA accounts for about 1.9% of Running Oak Capital LLC’s investment portfolio, making the stock its 15th largest holding. Running Oak Capital LLC’s holdings in IQVIA were worth $17,236,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Atlantic Union Bankshares Corp purchased a new position in IQVIA during the 3rd quarter valued at approximately $36,000. Bridges Investment Management Inc. boosted its position in shares of IQVIA by 2.2% during the 3rd quarter. Bridges Investment Management Inc. now owns 9,185 shares of the medical research company’s stock valued at $1,745,000 after acquiring an additional 198 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in shares of IQVIA by 56.4% in the third quarter. Jones Financial Companies Lllp now owns 6,115 shares of the medical research company’s stock valued at $1,098,000 after purchasing an additional 2,204 shares in the last quarter. Access Investment Management LLC bought a new stake in IQVIA in the third quarter worth $401,000. Finally, FDx Advisors Inc. purchased a new stake in IQVIA during the third quarter valued at $229,000. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on IQV. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $195.00 to $235.00 in a research note on Thursday, October 9th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday, January 25th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Robert W. Baird set a $258.00 target price on IQVIA and gave the company an “outperform” rating in a research report on Wednesday, October 29th. Finally, JPMorgan Chase & Co. raised their price target on IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $251.06.

IQVIA Trading Up 0.6%

Shares of IQV opened at $231.50 on Tuesday. The firm has a market capitalization of $39.42 billion, a price-to-earnings ratio of 31.76, a PEG ratio of 2.34 and a beta of 1.36. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04. The company has a 50-day moving average of $231.00 and a 200 day moving average of $209.37.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.